VIRTUAL Off-the-Shelf Allogeneic EBV T Cells: Ushering in the Next Wave of Innovation
Time: 3:00 pm
day: Bootcamp Day
Details:
- Discuss the journey that led to the historic EU approval of the first-ever allogeneic T-cell therapy globally
- Highlight the qualities that make allogeneic Epstein-Barr virus (EBV) T cells a highly versatile platform for targeting EBV-driven disease
- Explore how this platform can be modified with a chimeric antigen receptor (CAR) to target a wide range of non-EBV-associated disease
